Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia (LOHKALT)

17 november 2026 uppdaterad av: AstraZeneca

A Phase IV, Multicentre, Non-comparative, Open-label Study Evaluating the Safety and Effectiveness of Lokelma (Sodium Zirconium Cyclosilicate [SZC]) Administered Orally for the Treatment of Indian Patients With Hyperkalaemia

This is a Phase IV, multicentre, open-label, non-comparative study evaluating Lokelma (sodium zirconium cyclosilicate, SZC) in approximately 100 Indian adults with mild to moderate hyperkalaemia.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The primary objective is to assess safety through treatment-emergent adverse events, serious adverse events and discontinuations due to adverse events. Secondary objectives are to assess effectiveness of Lokelma through serum potassium reduction, achievement and maintenance of normokalaemia, while an exploratory objective focuses on continuation or initiation of RAAS inhibitor therapy. Each participant is followed for approximately 3.5 months, including treatment and a safety follow-up seven days after the final dose.

Studietyp

Interventionell

Inskrivning (Beräknad)

120

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Ahmedabad, Indien, 380052
        • Rekrytering
        • Research Site
      • Ahmedabad, Indien, 380013
        • Rekrytering
        • Research Site
      • Kolkata, Indien, 700020
        • Rekrytering
        • Research Site
      • Secunderabad, Indien, 500003
        • Rekrytering
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • • Participant must be ≥ 18 years of age, at the time of signing the informed consent.

    • Participants with mild to moderate hyperkalaemia- the potassium values between 5.1 to 6.4 mmol/L inclusive, at screening (Day 0)
    • Ability to have repeated blood draws or effective venous catheterisation.
    • Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. i) FOCBP must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening. The female participants should be on stable on their chosen method of birth control for minimum of one month before entering the study and willing to remain on the birth control until 7 days after the last dose. ii) Female participants who are surgically sterile or those who are post-menopausal (if they have been amenorrhoeic for 12 months prior to the planned date of screening without an alternative medical cause) are not considered to be of child-bearing potential.
    • Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria:

  • As judged by the investigator, any evidence of oedema which in the investigator's opinion makes it undesirable for the participant to participate in the study.

    • Patients undergoing haemodialysis or a prospective candidate for haemodialysis.
    • Pseudo hyperkalaemia signs and symptoms, such as excessive fist clenching haemolysed blood specimen, severe leucocytosis or thrombocytosis.
    • Participants with a life expectancy of < 12 months.
    • Participants who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the participants' tasks associated with the protocol.
    • Women who are pregnant, lactating, or planning to become pregnant.
    • Participants with diabetic ketoacidosis.
    • Presence of any condition which, in the opinion of the investigator, places the participant at undue risk.
    • Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
    • Participants with cardiac arrhythmias requiring immediate treatment.
    • Participants with history of QT prolongation associated with other medications that required discontinuation of that medication.
    • Participants with congenital long QT syndrome.
    • Participants treated with lactulose, rifaximin or other non-absorbed antibiotics for hyperammonaemia within the last 7 days.
    • Participants treated with resins (such as sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.
    • Participants treated with SPS or SZC (microporous, fractionated, protonated zirconium silicate), CPS or patiromer within the last 7 days.
    • Known hypersensitivity or previous anaphylaxis to SZC or to components or any of the excipients of the product.
    • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
    • Prior (within last 1 month) and ongoing participation in another clinical trial, observational study, and real-world evidence study.
    • Positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody, at screening.
    • Known to have tested positive for HIV.
    • Documented glomerular filtration rate < 15 mL/min/1.73 m2 within 90 days before study entry.
    • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
    • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Intervention

Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g

Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of TEAEs, SAEs, and DAEs.
Tidsram: Day 86

Number and proportion of participants with TEAEs SAEs, and DAEs. Incidence rates summarised by patients with events per 100 patient-years.

Day 86
Causal relationship of TEAEs, SAEs, and DAEs
Tidsram: Day 86

Nature, intensity and causal relationship of TEAEs, SAEs, and DAEs

Day 86

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Exponential rate of change in S-K values
Tidsram: Day 4

Rate of Change in S-K values

Day 4
Proportion of participants who achieve normokalaemia
Tidsram: Day 4

Number of study subjects achieving normal potassium levels

Day 4
Mean change and mean percent change from baseline in S-K values
Tidsram: Day 86

Mean change and mean percent change from baseline in S-K values over time until EOT

Day 86
Proportions of participants maintaining normokalaemia
Tidsram: Day 86

Number participants maintaining normal potassium levels at EOT

Day 86

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 augusti 2026

Primärt slutförande (Beräknad)

30 oktober 2027

Avslutad studie (Beräknad)

30 oktober 2027

Studieregistreringsdatum

Först inskickad

3 november 2026

Först inskickad som uppfyllde QC-kriterierna

17 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.

Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera